Amag Pharmaceuticals (AMAG) Stock Price & Overview
NASDAQ:AMAG
Current stock price
The current stock price of AMAG is 13.75 null. Today AMAG is up by 0.15%. In the past month the price increased by 0.88%. In the past year, price increased by 39.45%.
AMAG Key Statistics
- Market Cap
- 477.469M
- P/E
- N/A
- Fwd P/E
- 76.39
- EPS (TTM)
- -2.30
- Dividend Yield
- N/A
AMAG Stock Performance
AMAG Stock Chart
AMAG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AMAG. When comparing the yearly performance of all stocks, AMAG is one of the better performing stocks in the market, outperforming 88.08% of all stocks.
AMAG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMAG. Both the profitability and financial health of AMAG have multiple concerns.
AMAG Earnings
AMAG Forecast & Estimates
AMAG Financial Highlights
Over the last trailing twelve months AMAG reported a non-GAAP Earnings per Share(EPS) of -2.3. The EPS increased by 61.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -74.73% | ||
| ROA | -31% | ||
| ROE | N/A | ||
| Debt/Equity | 0.08 |
AMAG Ownership
About AMAG
Company Profile
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex', the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Company Info
Amag Pharmaceuticals
1100 WINTER STREET
WALTHAM MA 02451
CEO: William K. Heiden
Phone: 617-498-3300
Amag Pharmaceuticals / AMAG FAQ
What does AMAG do?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex', the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Can you provide the latest stock price for Amag Pharmaceuticals?
The current stock price of AMAG is 13.75 null. The price increased by 0.15% in the last trading session.
What is the dividend status of Amag Pharmaceuticals?
AMAG does not pay a dividend.
How is the ChartMill rating for Amag Pharmaceuticals?
AMAG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for AMAG stock?
Amag Pharmaceuticals (AMAG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.3).
What is the market capitalization of AMAG stock?
Amag Pharmaceuticals (AMAG) has a market capitalization of 477.47M null. This makes AMAG a Small Cap stock.